Home > Pulmonology > ERS 2022 > Mepolizumab beneficial for patients with severe eosinophilic asthma

Mepolizumab beneficial for patients with severe eosinophilic asthma

Presented By
Dr Rupert Jakes, GSK, UK
ERS 2022
In patients with severe eosinophilic asthma (SEA), continued reductions in clinically significant exacerbations (CSEs) were reported with the administration of mepolizumab after 2 years of follow-up. The current, real-world study confirmed the benefits of this IL-5 inhibitor in everyday practice. The prospective, observational, single-arm REALITI-A study investigated the real-world benefits of mepolizumab in patients with SEA (n=823). Patients received 12 months of pre-treatment prior to enrolment, standard-of-care plus mepolizumab, and were subsequently followed for 24 months. Outcomes included the rate of CSEs, the use of maintenance oral corticosteroids (mOCS), and exacerbations leading to hospital or emergency department (ED) admissions. The results after 1 year of follow-up have been reported previously [1]. Dr Rupert Jakes (GSK, UK) presented the trial results after an additional 12 months of follow-up [2]. After 2 years of follow-up, 73% of t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on